Compare UFG & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | LITS |
|---|---|---|
| Founded | 2021 | 2000 |
| Country | Singapore | United States |
| Employees | 26 | 4 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 25.7M |
| IPO Year | N/A | N/A |
| Metric | UFG | LITS |
|---|---|---|
| Price | $0.85 | $0.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 163.8K | ★ 520.2K |
| Earning Date | 04-22-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.69 |
| 52 Week High | $9.91 | $3.03 |
| Indicator | UFG | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 47.68 |
| Support Level | $0.78 | $0.69 |
| Resistance Level | $0.85 | $1.23 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 46.12 | 63.62 |
Uni-Fuels Holdings Ltd is a service provider of marine fuel solutions. It operates on an integrated business model, serving customers through two operating models: sales of marine fuels solutions and brokerage (i.e., acting as an intermediary between marine fuels suppliers and customers for a commission). The various marine fuel products offered by the company include very low sulfur fuel oil, high sulfur fuel oil, marine gas oil, and bio marine fuel. Its customers are mainly shipping companies and other fuel suppliers operating in market sectors such as bulk, tanker, offshore, container, general cargo, tug and barge, car carrier, cruise, yacht, and dredging. Geographically, the company derives maximum revenue from Singapore, and the rest from Malaysia, Hong Kong, China, and other regions.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.